Blood hemoperfusion with resin adsorption combined continuous veno-venous hemofiltration for patients with multiple organ dysfunction syndrome

Liu, Luyi; Zhu, Yongjian; Li, Xiaoli; Liang, Yafeng; Liang, Zuo-peng; Yujun, Xia

doi:10.5847/wjem.j.issn.1920-8642.2012.01.008

Cited by 5 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HA-type HP device uses a neutral macroporous adsorption resin as an adsorbent, which can adsorb medium and large molecules of cytokines and inflammatory factors [9] so as to make up for the shortcomings of CVVH. Previous studies have found that CVVH combined with HP can clear various inflammatory mediators more effectively than CVVH alone [21]. Li et al [22] also suggested that CVVH combined with HP could better remove toxic metabolites and inflammatory mediators in SAP than HP alone, and it not only shortens the time of symptoms disappearing but also decreases the incidence of complications and the mortality.…”

Section: Discussionmentioning

confidence: 99%

Prolonged Intermittent Renal Replacement Therapy Combined with Hemoperfusion Can Improve Early Recovery of Moderate and Severe Acute Pancreatitis, Especially in Patients with Acute Kidney Injury

et al. 2022

View full text Add to dashboard Cite

Introduction: The aim of this study was to investigate the efficacy of prolonged intermittent renal replacement therapy (PIRRT) plus hemoperfusion (HP) in treating moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP). Methods: A total of 105 MSAP and SAP patients were enrolled. Sixty of them received routine internal medical therapy (control group), and 45 received PIRRT and HP in addition to routine internal medical therapy (PIRRT + HP group). The vital signs, laboratory results, and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score were compared between the two groups before treatment and on the 3rd and 7th days of treatment. Results: No deaths or treatment-related serious adverse reactions occurred in both groups. After 3 and 7 days of treatment, the APACHE II score decreased more significantly in the PIRRT + HP group than in the control group (3 days: 5.47 [±3.30] vs. 7.53 [±3.89], p = 0.005. 7 days: 4.82 [±3.49] vs. 6.87 [±3.54], p = 0.004). After 3 days of treatment, the inflammatory combination parameters systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) in the PIRRT + HP group decreased more significantly than those in the control group (SII: 1,239.00 [737.80–1,769.00] vs. 2,013.00 [1,260.00–3,167.00], p = 0.001. NLR: 8.78 [±4.52] vs. 11.88 [±7.30], p = 0.009). After 7 days of treatment, SII, NLR, and hypersensitive C-reactive protein decreased significantly compared with baseline, but no statistical differences between the two groups were observed. AST in both groups remained stable with treatment. There was no significant difference in baseline creatinine between the two groups of AKI patients, but after 3 and 7 days of treatment, the proportion of acute kidney injury (AKI) patients in the PIRRT + HP group whose creatinine decreased by 50% from baseline or fell to the normal range was significantly higher than that in the control group (p < 0.05). Conclusion: PIRRT + HP therapy could not only improve the general conditions, as measured by APACHE II score, but also reduce the inflammatory cascade of patients with acute pancreatitis. For MSAP and SAP patients complicated with AKI, this therapy may accelerate the recovery of renal function.

show abstract

Section: Discussionmentioning

confidence: 99%

Prolonged Intermittent Renal Replacement Therapy Combined with Hemoperfusion Can Improve Early Recovery of Moderate and Severe Acute Pancreatitis, Especially in Patients with Acute Kidney Injury

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most studies chose IL-6 as a removable key cytokine in inflammation progression, and it is considered as the cartridge adequacy index. [ 14 23 24 25 ] On the other hand, with an interesting pattern, C- reactive protein (HS-CRP) and ferritin, as two major acute-phase proteins, had a good correlation with IL-6 and IL-18, respectively, and both increase during inflammation due to a bacterial or viral infection. [ 26 ] Therefore, we chose HS-CRP and ferritin as the representative molecules for verification of the ability of HA280 resin cartridge to eliminate cytokines.…”

Section: Discussionmentioning

confidence: 99%

Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not?

Abbasi

Naderi

Amra

et al. 2021

Journal of Research in Medical Sciences

View full text Add to dashboard Cite

Background: The new coronavirus outbreak quickly filled hospital beds and stunned the world. Intensive care is required for 5% of patients, and the mortality rate for critically ill patients is 49%. The “cytokine storm” is considered as the main cause of pathogenesis for coronavirus disease-19 (COVID-19)-related respiratory failure, hemoperfusion may be a modality for treatment of disease. Materials and Methods: Thirty-seven an patients with positive real-time polymerase chain reaction for SARStions2 in an upper respiratory tract sample or typical chest computed tomography lesion were eligible for this case–control study. Patients meeting the criteria for hemoperfusion including clinical and laboratory indices, were evaluated for outcomes such as hospitalization length and mortality. Patients were divided into three groups, i.e., patients who received hemoperfusion without a need for mechanical ventilation (MV), patients who received hemoperfusion before MV, and patients who received hemoperfusion after MV. Results: Among 37 patients with COVID-19 respiratory failure, 32% were female with a mean age of 55.54 (standard deviation 14.1) years. There was no statistically significant difference between the three groups in terms of length of hospital stay and intensive care unit (ICU) stay (P-tayns: 0.593 and 0.243, respectively, confidence interval [CI]: 95%). Heart rate, respiratory rate, PaO2/FIO2, high-sensitivity C-reactive protein, and ferritin significantly improved after the application of hemoperfusion in all groups (P < 0.05, CI: 95%). Conclusion: It seems that applying hemoperfusion in the inflammatory phase of the disease, especially before the intubation, reduce the need for MV. However, hemoperfusion does not have any impacts on the duration of hospital and ICU stay.

show abstract

“…However, some studies reported that combined HP-hemodialysis for poisoning resulted from large doses of methotrexate or phenytoin, with a higher protein binding rate, can provide the better results of poison clearance. [7][8][9] Currently, the timing of the treatment depends on the clinical experience of doctors. HP treatment of patients with acute poisoning usually lasts 2 to 3 hours.…”

Section: Discussionmentioning

confidence: 99%

Effect of hemoperfusion cartridge on different internal environmental indicators

Wang

Eric

et al. 2013

World Journal of Emergency Medicine

View full text Add to dashboard Cite

show abstract

Blood hemoperfusion with resin adsorption combined continuous veno-venous hemofiltration for patients with multiple organ dysfunction syndrome

Cited by 5 publications

References 12 publications

Prolonged Intermittent Renal Replacement Therapy Combined with Hemoperfusion Can Improve Early Recovery of Moderate and Severe Acute Pancreatitis, Especially in Patients with Acute Kidney Injury

Prolonged Intermittent Renal Replacement Therapy Combined with Hemoperfusion Can Improve Early Recovery of Moderate and Severe Acute Pancreatitis, Especially in Patients with Acute Kidney Injury

Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not?

Effect of hemoperfusion cartridge on different internal environmental indicators

Contact Info

Product

Resources

About